Clinical trials: Congestive Cardiac Failure
Cardiovascular Diseases, Heart Diseases
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
The purpose of this study is to evaluate the effectiveness of aldosterone antagonist therapy in reducing cardiovascular mortality, aborted cardiac arrest, and heart failure hospitalization in patients who have heart failure with…
- Conditions
- Cardiovascular Diseases, Heart Diseases, Heart Failure, Congestive
- Trial name
- TOPCAT (NCT00094302)
- Testing
- Spironolactone
- Where
- 270 sites in United States, Argentina and 4 more
- Volunteers
- 3,445 people
- Sponsor
- Carelon Research
Atrial Fibrillation, Congestive Heart Failure
Investigational Device Exemption (IDE) Study for the Approval of Closed Loop Stimulation (CLS) and Cardiac Resyncronization Pacing Therapies (CRT) for the Treatment of Atrial Fibrillation (AF) With Ablate and Pace
The purpose of this study is to demonstrate the safety and effectiveness of biventricular pacing over conventional right ventricular pacing in patients with persistent or permanent, symptomatic atrial fibrillation undergoing…
- Trial name
- AVAIL (NCT00356057)
- Testing
- Protos DR/CLS and Stratos LV CRT pacemakers
- Where
- 10 sites in United States
- Volunteers
- 153 people
- Sponsor
- Biotronik, Inc.
Venous Thromboembolism
Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
The purpose of this study is to compare the efficacy and safety of dalteparin vs unfractionated heparin for the prevention of VTE (Venous Thromboembolism) in hospitalized acutely ill medical patients.
- Trial name
- NCT00445328
- Testing
- Dalteparin (Fragmin), Unfractionated heparin
- Where
- 7 sites in India
- Volunteers
- 84 people
- Sponsor
- Pfizer
Heart Failure, Congestive Heart Failure
Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)
The NECTAR-HF feasibility trial is designed to evaluate the application of right vagal nerve stimulation in heart failure patients with a New York Heart Association Class III, an ejection fraction equal to or less than 35 %, and…
- Trial name
- NECTAR-HF (NCT01385176)
- Testing
- Implant of investigational device system, Titration during the randomization phase, Titration after the randomization phase
- Where
- 21 sites in Belgium, Czechia and 6 more
- Volunteers
- 118 people
- Sponsor
- Boston Scientific Corporation
Cardiac Failure Aggravated
Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure
Primary Objectives: Assess the safety and tolerability of sotagliflozin in hemodynamically stable participants with worsening of heart failure, compared to placebo.
- Trial name
- NCT03292653
- Testing
- Sotagliflozin
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 32 people
- Sponsor
- Lexicon Pharmaceuticals
Myocardial Infarction
Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
The purpose of this study is to determine whether Allogeneic Cardiosphere-Derived Cells (CAP-1002) is safe and effective in decreasing infarct size in patients with a myocardial infarction.
- Trial name
- ALLSTAR (NCT01458405)
- Testing
- CAP-1002 Allogeneic Cardiosphere-Derived Cells
- Where
- 32 sites in United States
- Volunteers
- 135 people
- Sponsor
- Capricor Inc.
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Early Warning System
The study will begin in 2013 whereby patients having an early warning system (EWS) alert will be randomized to be seen by the rapid response team (RRT) for triage versus usual care.
- Conditions
- Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Cancer, Diabetes Mellitus
- Trial name
- NCT01741480
- Testing
- Early warning system monitoring., routine care
- Where
- United States
- Volunteers
- 571 people
- Sponsor
- Washington University School of Medicine
Cancer, Congestive Heart Failure
Expanding Access to Home-Based Palliative Care
This study will test the effectiveness of integrating an evidence-based model of home-based palliative (HBPC) within primary care clinics on patient and caregiver outcomes.
- Conditions
- Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT03128060
- Testing
- Home-based palliative care, Enhanced usual care
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Southern California
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Comparative Effectiveness of Telemedicine in Primary Care
Leveraging a natural experiment approach, the investigators will examine rapidly changing telemedicine and in-person models of care during and after the COVID-19 crisis to determine whether certain patients could safely choose to…
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure, Diabetes
- Trial name
- NCT04684836
- Testing
- Exposure to telemedicine, after the onset of the pandemic
- Where
- 4 sites in United States
- Volunteers
- 33,100 people
- Sponsor
- Weill Medical College of Cornell University
Diabetes, Asthma
Integrated Care (IC) Models for Patient-Centered Outcomes
Multiple chronic conditions (MCC) are widely recognized as the U.S. public health challenge of the 21st century. These physical and behavioral health conditions take a large toll on those living with chronic diseases, including…
- Conditions
- Diabetes, Asthma, Chronic Obstructive Pulmonary Disease, Hypertension
- Trial name
- IC (NCT03451630)
- Testing
- High-Touch, High-Tech, Optimal Discharge Planning
- Where
- United States
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Congestive Heart Failure, Heart Failure, Diastolic
Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs
Perform a randomized, double blind, placebo-controlled Phase 2a feasibility study to determine whether treatment of HFpEF patients with intracoronary allogeneic CDCs affects clinical functional status (QOL scores), exercise…
- Trial name
- RegressHFpEF (NCT02941705)
- Testing
- Allogeneic Derived Cells
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Cedars-Sinai Medical Center
Heart Failure, Heart Failure, Systolic
Hemodynamic-GUIDEd Management of Heart Failure
The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS™ HF System in an expanded patient population including heart failure (HF) patients outside of the present indication, but at risk for…
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure NYHA Class II
- Trial name
- GUIDE-HF (NCT03387813)
- Testing
- CardioMEMS™ HF System
- Where
- 129 sites in United States, Canada
- Volunteers
- 2,358 people
- Sponsor
- Abbott Medical Devices
Congestive Heart Failure
Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure
This study is being done to determine the effects of subcutaneous (under the skin) injection of human B-type natriuretic factor (BNP), Natrecor (nesiritide), a hormone produced by the heart, in combination with Tadalafil on: The…
- Trial name
- NCT01544998
- Testing
- Nesiritide, Tadalafil, Saline load
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Mayo Clinic
Death, Congestive Heart Failure
Impact of Heart Failure Center Program on Cardiac Outcomes in Patients With Heart Failure
Congestive heart failure (CHF) is a major public health problem worldwide. CHF carries a devastating prognosis, which resembles that of some types of malignant cancer.
- Trial name
- NCT01416285
- Where
- Taiwan
- Volunteers
- 470 people
- Sponsor
- Chang Gung Memorial Hospital
Mitral Valve Insufficiency, Heart Failure
Effectiveness of Surgical Mitral Valve Repair Versus Medical Treatment for People With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure
Mitral regurgitation (MR), also known as mitral insufficiency, is a condition in which the heart's mitral valve, located between two of the heart's main chambers, does not firmly shut, allowing blood to leak backwards within the…
- Trial name
- SMMART-HF (NCT00608140)
- Testing
- Surgical mitral valvuloplasty with placement of annular ring (SMVR), Optimal medical therapy (OMT)
- Where
- 9 sites in United States, Canada
- Volunteers
- 2 people
- Sponsor
- Duke University
Congestive Heart Failure, Diabetes Mellitus
Glycemic Control and Variability for Congestive Heart Failure Exacerbation
High glucose as well as fluctuations (rapid swings) in blood glucose can contribute to severe hospital complications and even death.
- Trial name
- NCT00812487
- Testing
- Intravenous insulin, Subcutaneous insulin
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Kathleen Dungan
Congestive Heart Failure, Diabetes Mellitus
Intensive Glycemic Control for Congestive Heart Failure Exacerbation
Patients with heart failure often have high blood sugar (glucose).
- Trial name
- NCT00812253
- Testing
- Intravenous insulin, Subcutaneous insulin
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Kathleen Dungan
Influenza, Pneumonia
Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years
The overall objective of this study is to describe the effectiveness of Flublok Quadrivalent vaccine compared to standard dose inactivated influenza vaccine (SD-IIV) in adults 18 through 64 years of age.
- Conditions
- Influenza, Pneumonia, Lower Respiratory Tract Infection, Acute Myocardial Infarction
- Trial name
- NCT03694392
- Testing
- Flublok Quadrivalent, Standard Dose Inactivated Influenza Vaccine (SD-IIV)
- Where
- United States
- Volunteers
- 2,776,278 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Heart Failure, Congestive
TReatment of Atrial Fibrillation With Dual dEfibrillator in Heart Failure Patients
Demonstrate the efficacy of the device-based managed therapy to treat atrial tachycardia and fibrillation (AT/AF) in patients with CHF indication for implant of a CRT defibrillator and to demonstrate the advantage of automatic…
- Trial name
- TRADE HF (NCT00345592)
- Testing
- Dual (atrial and ventricular) implantable defibrillator
- Where
- 2 sites in Italy
- Volunteers
- 420 people
- Sponsor
- Boston Scientific Corporation
Congestive Heart Failure
Phase I Study of OPC-61815
To investigate the effects of intravenous administration of OPC-61815 at 16 and 32 mg on QT/QTc interval in healthy male subjects
- Trial name
- NCT03510663
- Testing
- OPC-61815 16mg, OPC-61815 32mg, Moxifloxacin
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.